EUVIMEDEUVIMED entdecken
Crossref

Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era

Atsushi Jinguji, Shuhei Kurosawa, Takashi Toya, Kana Kato, Yasutaka Sadaga, Kaori Kondo, Fumihiko Ouchi, Masashi Shimabukuro, Naoki Shingai, Hiroaki Shimizu, Yuho Najima, Kyoko Haraguchi und 1 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · e740-e751.e6

DOI: 10.1016/j.clml.2026.03.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Atsushi Jinguji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: FLT3 mutations in acute myeloid leukemia (AML) are associated with high relapse rates even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). OBJECTIVES: We evaluated changes in transplant outcomes in patients with FLT3-ITD-mutated AML and detailed real-world experiences with post-transplant gilteritinib maintenance. STUDY DESIGN: This study included adult patients (≥16 years) with FLT3-ITD-mutated AML who were eligible for allo-HSCT. The patients were stratified into the FLT3i era (2019-2024) and the pre-FLT3i era (2012-2018). The primary endpoint was the 3-year overall survival (OS). RESULTS: Ninety-three patients were included, 43 in the pre-FLT3i era and 50 in the FLT3i era. The FLT3i era was associated with a significantly higher 3-year OS from diagnosis (65.7% vs. 44.3%; 95% CI, 48.0-78.6 vs. 28.9-58.6). Thirty-eight patients and 48 patients, respectively, underwent allo-HSCT. The 3-year OS from allo-HSCT was 47.4% (95% CI, 31.0-62.1) and 60.6% (95% CI, 41.8-75.0), respectively (P = .11). Multivariate analysis revealed that myelodysplastic change, non-CR disease status at allo-HSCT, and a higher HCT-CI (≥2) were adverse prognostic factors. In the FLT3i era, 6 patients received maintenance therapy with gilteritinib. The median interval from HSCT to the initiation of gilteritinib was 30 days (range, 18-69). Five patients remained relapse-free, with a median treatment duration of 583 days. The 2-year OS rate was 83.3% (95% CI, 27.3-97.5). CONCLUSIONS: Although the OS from diagnosis improved significantly in the FLT3i era, relapse after allo-HSCT remained a substantial challenge. Further studies are needed to optimize FLT3i maintenance therapy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteProtein Kinase InhibitorsHumansFemaleAdultMiddle AgedMaleTransplantation, HomologousMutationYoung AdultTreatment OutcomeAdolescentAgedAniline CompoundsPyrazines

Stichwörter der Autor:innen

FLT3 inhibitorsacute myeloid leukemiaallogeneic hematopoietic stem cell transplantationgilteritinib

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase InhibitorsgilteritinibAniline CompoundsPyrazines

Autor:innen und Institutionen

  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan. Electronic address: tooya…

Zitieren

APA

Jinguji, A., Kurosawa, S., Toya, T., Kato, K., Sadaga, Y., Kondo, K., Ouchi, F., Shimabukuro, M., Shingai, N., Shimizu, H., Najima, Y., Haraguchi, K., & Doki, N. (2026). Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era. Clinical Lymphoma Myeloma and Leukemia, 26(6), e740-e751.e6. https://doi.org/10.1016/j.clml.2026.03.007

Vancouver

Jinguji A, Kurosawa S, Toya T, Kato K, Sadaga Y, Kondo K, et al. Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):e740-e751.e6. doi:10.1016/j.clml.2026.03.007

BibTeX
@article{Jinguji2026,
  author = {Jinguji, Atsushi and Kurosawa, Shuhei and Toya, Takashi and Kato, Kana and Sadaga, Yasutaka and Kondo, Kaori and Ouchi, Fumihiko and Shimabukuro, Masashi and Shingai, Naoki and Shimizu, Hiroaki and Najima, Yuho and Haraguchi, Kyoko and Doki, Noriko},
  title = {Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {e740--e751.e6},
  doi = {10.1016/j.clml.2026.03.007}
}
Kostenlos starten →